Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 3-year efficacy and safety results from phase 3 future 1 trial

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/25726

Title:	Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 3-year efficacy and safety results from phase 3 future 1 trial
Authors:	Mease, Philip J. Kavanaugh, Arthur Reimold, Andreas Tahir, Hasan Rech, Juergen Hall, Stephen GEUSENS, Piet Pascale, Pellet Delicha, Evie Marie Pricop, Luminata Mpofu, Shepard
Issue Date:	2017
Publisher:	BMJ PUBLISHING GROUP
Source:	ANNALS OF THE RHEUMATIC DISEASES, 76, p. 952-953 (Art N° SAT0470)
Notes:	[Mease, P. J.] Swedish Med Ctr, Seattle, WA USA. [Mease, P. J.] Univ Washington, Seattle, WA 98195 USA. [Kavanaugh, A.] UC San Diego Sch Med, La Jolla, CA USA. [Reimold, A.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA. [Tahir, H.] Barts Hlth NHS Trust, London, England. [Rech, J.] Univ Erlangen Nurnberg, Erlangen, Germany. [Hall, S.] Monash Univ, Melbourne, Vic, Australia. [Geusens, P.] Univ Hasselt, Hasselt, Belgium. [Geusens, P.] Maastricht Univ Hosp, Maastricht, Netherlands. [Pascale, P.; Delicha, E. M.; Mpofu, S.] Novartis Pharma AG, Basel, Switzerland. [Pricop, L.] Novartis Pharmaceut, E Hanover, NJ USA.
Keywords:	monoclonal antibodies; Psoriatic arthritis; randomized trials and safety
Document URI:	http://hdl.handle.net/1942/25726
Link to publication/dataset:	http://ard.bmj.com/content/76/Suppl_2/952
ISSN:	0003-4967
e-ISSN:	1468-2060
DOI:	10.1136/annrheumdis-2017-eular.1260
ISI #:	000413181402756
Category:	M
Type:	Journal Contribution
Appears in Collections:	Research publications

File	Description	Size	Format
10.1136@annrheumdis-2017-eular.1260.pdf Restricted Access	Published version	562.59 kB	Adobe PDF	View/Open Request a copy

7

checked on Apr 22, 2024

24

checked on Sep 5, 2022

14

checked on Sep 5, 2022

Check